Reynolds et al. reported that adenoviral BMPR2 delivery attenuates vascular remodeling in PAH animal models and treatment with BMPR2 ligands ameliorates TGFβ1-induced EndMT in vitro [36]. Here, BMPR2 is linked to pulmonary arterial hypertension.